C3N-01846
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69.86447639
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- HEDGEHOG_SIGNALING+0.260
- HYPOXIA+0.260
- MTORC1_SIGNALING+0.230
- CHOLESTEROL_HOMEOSTASIS+0.210
- GLYCOLYSIS+0.210
- MYC_TARGETS_V2+0.190
- PANCREAS_BETA_CELLS+0.180
- MYOGENESIS+0.170
- KRAS_SIGNALING_DN+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.440
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- COMPLEMENT-0.300
- INFLAMMATORY_RESPONSE-0.250
- KRAS_SIGNALING_UP-0.190
- BILE_ACID_METABOLISM-0.170
- FATTY_ACID_METABOLISM-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.771 |
| 2 | SRR2932825 | — | — | 0.766 |
| 3 | 20120162.TNBC | — | E | 0.724 |
| 4 | TCGA-63-5128-01A-01R-1443-07 | — | cohortSQ2 | 0.724 |
| 5 | SRR2932826 | — | — | 0.722 |
| 6 | TCGA-43-7657-01A-31R-2125-07 | — | cohortSQ1 | 0.722 |
| 7 | SRR2016936 | — | — | 0.719 |
| 8 | C3L-00445 | — | cohortSQ2 | 0.717 |
| 9 | TCGA-98-8021-01A-11R-2247-07 | — | cohortSQ1 | 0.714 |
| 10 | TCGA-NC-A5HP-01A-11R-A26W-07 | — | cohortSQ1 | 0.713 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |